The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Early changes in peripheral blood neutrophil-lymphocyte ratio (NLR) to predict outcomes with immune checkpoint inhibitors (ICIs) for metastatic urothelial carcinoma (mUC).
 
Jonathan Thomas
No Relationships to Disclose
 
Irbaz Bin Riaz
No Relationships to Disclose
 
Dory Freeman
No Relationships to Disclose
 
Elio Adib
Employment - Amgen (I)
 
Pier Vitale Nuzzo
No Relationships to Disclose
 
Talal El Zarif
No Relationships to Disclose
 
Matthew Davidsohn
No Relationships to Disclose
 
Heather McClure
No Relationships to Disclose
 
Catherine Curran
Stock and Other Ownership Interests - Alnylam
Research Funding - Alnylam
 
Praful Ravi
No Relationships to Disclose
 
Ritu Yadav
No Relationships to Disclose
 
Uttam Kalluri
No Relationships to Disclose
 
Jana Zeineddine
No Relationships to Disclose
 
Ayah Matar
No Relationships to Disclose
 
Bradley Alexander McGregor
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Dendreon; Eisai; EMD Serono; Exelixis; Genentech/Roche; Janssen Oncology; Nextar; Pfizer; Seattle Genetics/Astellas
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Pfizer/EMD Serono (Inst); Seattle Genetics/Astellas (Inst)
 
Charlene Mantia
Research Funding - Bristol-Myers Squibb (Inst)
 
Guru P. Sonpavde
Honoraria - UpToDate
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Eisai; EMD Serono; Exelixis; G1 Therapeutics; Genentech; Gilead Sciences; Infinity Pharmaceuticals; Janssen; Loxo/Lilly; Merck; Pfizer; Scholar Rock; Seagen
Speakers' Bureau - Medscape; Onclive; Physicans' Education Resource; Research to Practice
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Gilead Sciences (Inst); Janssen (Inst); Predicine (Inst); QED Therapeutics (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
Other Relationship - Astellas Pharma; AstraZeneca; Bavarian Nordic; Bristol-Myers Squibb; Debiopharm Group; Elsevier; G1 Therapeutics; Mereo BioPharma; QED Therapeutics